BlackRock Fund Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

BlackRock Fund Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$9K	Hold	632	–	–	﹤0.01%	3979
2016 Q3	$8K	Buy	632 +27	+4%	+$262	﹤0.01%	3997
2016 Q2	$6K	Sell	605 -67,014	-99%	-$804K	﹤0.01%	4064
2016 Q1	$568K	Sell	67,619 -2,265	-3%	-$18.9K	﹤0.01%	3225
2015 Q4	$861K	Sell	69,884 -53,293	-43%	-$1.46M	﹤0.01%	3245
2015 Q3	$7.5M	Buy	123,177 +5,472	+5%	+$395K	﹤0.01%	2554
2015 Q2	$9.19M	Buy	117,705 +24,492	+26%	+$2.06M	﹤0.01%	2558
2015 Q1	$6.33M	Buy	93,213 +4,381	+5%	+$376K	﹤0.01%	2708
2014 Q4	$8.24M	Buy	88,832 +8,299	+10%	+$858K	﹤0.01%	2575
2014 Q3	$8.48M	Buy	80,533 +8,336	+12%	+$1.16M	﹤0.01%	2451
2014 Q2	$10.3M	Buy	72,197 +2,170	+3%	+$317K	﹤0.01%	2393
2014 Q1	$10.6M	Buy	70,027 +4,509	+7%	+$888K	﹤0.01%	2373
2013 Q4	$12M	Buy	65,518 +11,064	+20%	+$2.03M	﹤0.01%	2278
2013 Q3	$12M	Buy	54,454 +6,750	+14%	+$1.44M	﹤0.01%	2244
2013 Q2	$8.33M	Buy	+47,704	New	+$12.4M	﹤0.01%	2367

Other funds holding MDGL

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

BlackRock Fund Advisors's MDGL Position: Q4 2016 in Review

BlackRock Fund Advisors held its Madrigal Pharmaceuticals (MDGL) position steady in Q4 2016 at 632 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #3979.

BlackRock Fund Advisors first reported a position in MDGL in Q2 2013 and has held it in 15 quarters since. The position peaked at $12M in Q3 2013. 31 funds tracked by Wall St. Rank hold MDGL as of Q4 2016.

BlackRock Fund Advisors held 632 shares of Madrigal Pharmaceuticals worth $9K as of Q4 2016.
BlackRock Fund Advisors left its Madrigal Pharmaceuticals share count unchanged in Q4 2016.
Madrigal Pharmaceuticals made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3979 holding.
BlackRock Fund Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Madrigal Pharmaceuticals position peaked at $12M in Q3 2013.
31 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.